281 related articles for article (PubMed ID: 17224002)
1. Acute and chronic neuroendocrine effects of interferon-beta 1a in multiple sclerosis.
Then Bergh F; Kümpfel T; Yassouridis A; Lechner C; Holsboer F; Trenkwalder C
Clin Endocrinol (Oxf); 2007 Feb; 66(2):295-303. PubMed ID: 17224002
[TBL] [Abstract][Full Text] [Related]
2. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients.
Kümpfel T; Schwan M; Pollmächer T; Yassouridis A; Uhr M; Trenkwalder C; Weber F
Mult Scler; 2007 Nov; 13(9):1138-45. PubMed ID: 17967841
[TBL] [Abstract][Full Text] [Related]
3. Adenohypophyseal function in bitches treated with medroxyprogesterone acetate.
Beijerink NJ; Bhatti SF; Okkens AC; Dieleman SJ; Mol JA; Duchateau L; Van Ham LM; Kooistra HS
Domest Anim Endocrinol; 2007 Feb; 32(2):63-78. PubMed ID: 16455223
[TBL] [Abstract][Full Text] [Related]
4. Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids.
Gudbjörnsson B; Skogseid B; Oberg K; Wide L; Hällgren R
J Rheumatol; 1996 Apr; 23(4):596-602. PubMed ID: 8730111
[TBL] [Abstract][Full Text] [Related]
5. Effects of interferon-beta 1a on the hypothalamic-pituitary-adrenal axis, leukocyte distribution and mood states in multiple sclerosis patients: results of a 1-year follow-up study.
Goebel MU; Czolbe F; Becker H; Janssen OE; Schedlowski M; Limmroth V
Eur Neurol; 2005; 53(4):182-7. PubMed ID: 15947464
[TBL] [Abstract][Full Text] [Related]
6. [Interferon-beta 1a in relapsing-remitting multiple sclerosis. First report of a Mexican population].
León C; Violante A; Arriada N; Santana HR; Corona T
Rev Neurol; 2000 Dec 1-15; 31(11):1019-22. PubMed ID: 11190865
[TBL] [Abstract][Full Text] [Related]
7. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
8. Low serum dehydroepiandrosterone sulfate in women with primary Sjögren's syndrome as an isolated sign of impaired HPA axis function.
Valtysdóttir ST; Wide L; Hällgren R
J Rheumatol; 2001 Jun; 28(6):1259-65. PubMed ID: 11409117
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal neuroendocrine changes assessed by dexamethasone/CRH and growth hormone releasing hormone tests in psychotic depression.
Owashi T; Otsubo T; Oshima A; Nakagome K; Higuchi T; Kamijima K
Psychoneuroendocrinology; 2008 Feb; 33(2):152-61. PubMed ID: 18068306
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
[TBL] [Abstract][Full Text] [Related]
11. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis.
Ysrraelit MC; Gaitán MI; Lopez AS; Correale J
Neurology; 2008 Dec; 71(24):1948-54. PubMed ID: 19064876
[TBL] [Abstract][Full Text] [Related]
12. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis.
Gottschalk M; Kümpfel T; Flachenecker P; Uhr M; Trenkwalder C; Holsboer F; Weber F
Arch Neurol; 2005 Feb; 62(2):277-80. PubMed ID: 15710856
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
[TBL] [Abstract][Full Text] [Related]
14. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of the hypothalamo-pituitary axis in rheumatoid arthritis.
Jorgensen C; Bressot N; Bologna C; Sany J
J Rheumatol; 1995 Oct; 22(10):1829-33. PubMed ID: 8991978
[TBL] [Abstract][Full Text] [Related]
16. Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus.
Köller MD; Templ E; Riedl M; Clodi M; Wagner O; Smolen JS; Luger A
Ann Rheum Dis; 2004 Dec; 63(12):1677-80. PubMed ID: 15082470
[TBL] [Abstract][Full Text] [Related]
17. [Safety and tolerability in the early phase of slow schedule versus fast schedule treatment with 44 micrograms of interferon beta-1a in patients with multiple sclerosis (PARALEN study)].
Hernandez-Perez MA;
Rev Neurol; 2009 May 16-31; 48(10):505-8. PubMed ID: 19434583
[TBL] [Abstract][Full Text] [Related]
18. Suppression and recovery of the hypothalamic function after high-dose corticosteroid treatment in preterm infants.
Ng PC; Lam CW; Lee CH; Chan IH; Wong SP; Fok TF
Neonatology; 2008; 94(3):170-5. PubMed ID: 18612214
[TBL] [Abstract][Full Text] [Related]
19. Effects of different treatments for hyperthyroidism on the hypothalamic-pituitary-adrenal axis.
Lizcano F; Salvador J
Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):1085-90. PubMed ID: 18505442
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of endocrine profile, hypothalamic-pituitary-testis axis and semen quality in multiple sclerosis.
Safarinejad MR
J Neuroendocrinol; 2008 Dec; 20(12):1368-75. PubMed ID: 19094084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
